Ethamoxytriphetol
Overview of the chemical compound Ethamoxytriphetol
Ethamoxytriphetol, also known by its developmental code name MER-25, is a nonsteroidal selective estrogen receptor modulator (SERM) that was developed in the 1960s. It was one of the first compounds to be identified with antiestrogenic properties, and it has been used primarily in scientific research to study the effects of estrogen receptor modulation.
Chemical Structure and Properties[edit | edit source]
Ethamoxytriphetol is a triphenylethylene derivative, which is a class of compounds known for their ability to interact with estrogen receptors. The chemical structure of Ethamoxytriphetol is characterized by three phenyl rings and an ether linkage, which contribute to its binding affinity and selectivity for estrogen receptors.
Mechanism of Action[edit | edit source]
As a SERM, Ethamoxytriphetol exhibits both estrogenic and antiestrogenic effects depending on the tissue type. It acts as an antagonist in some tissues, such as the breast, where it blocks the effects of estrogen, and as an agonist in others, such as bone and the cardiovascular system, where it mimics the effects of estrogen. This dual action is due to its ability to bind to estrogen receptors and modulate their activity in a tissue-selective manner.
Pharmacological Effects[edit | edit source]
Ethamoxytriphetol was initially investigated for its potential use in treating estrogen-dependent conditions such as breast cancer and endometriosis. However, its development for clinical use was discontinued due to the availability of more effective and selective agents. Despite this, Ethamoxytriphetol remains a valuable tool in research for understanding the role of estrogen receptors in various physiological and pathological processes.
Research Applications[edit | edit source]
In scientific research, Ethamoxytriphetol has been used to study the mechanisms of estrogen receptor modulation and the effects of estrogen on different tissues. It has provided insights into the development of newer SERMs with improved efficacy and safety profiles. Researchers continue to use Ethamoxytriphetol to explore the complex interactions between estrogen receptors and their ligands.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
